2023
RNA m6A methylation in psychiatric disorders.
Mao Q, Luo J, Luo X, Zhu X, Wang K, Zuo L, Zhang Y, Luo X. RNA m6A methylation in psychiatric disorders. EC Psychology And Psychiatry 2023, 12 PMID: 38145106, PMCID: PMC10745284.Peer-Reviewed Original ResearchMajor psychiatric disordersPsychiatric disordersM6A modificationM6A methyltransferase METTL3Synaptic protein synthesisInflammatory infiltrationImmune infiltrationRNA m6A methylationTherapeutic targetM6A regulatorsAlzheimer's diseaseNeuropsychiatric disordersMethyltransferase METTL3Subtype classificationPromising targetDiseaseDisordersM6A methylationInfiltrationCritical roleProtein synthesisReviewPathogenesisComprehensive reviewPreventionPleiotropic Association of CACNA1C Variants With Neuropsychiatric Disorders
Wang Z, Lin X, Luo X, Xiao J, Zhang Y, Xu J, Wang S, Zhao F, Wang H, Zheng H, Zhang W, Lin C, Tan Z, Cao L, Wang Z, Tan Y, Chen W, Cao Y, Guo X, Pittenger C, Luo X. Pleiotropic Association of CACNA1C Variants With Neuropsychiatric Disorders. Schizophrenia Bulletin 2023, 49: 1174-1184. PMID: 37306960, PMCID: PMC10483336, DOI: 10.1093/schbul/sbad073.Peer-Reviewed Original ResearchConceptsGray matter volumeBipolar disorderNeuropsychiatric disordersIntracranial volumeSingle nucleotide polymorphismsParkinson's diseaseCACNA1C variantsCACNA1C mRNARisk allelesAlcohol use disorderAverage cortical thicknessTotal intracranial volumeMultiple psychiatric disordersFalse discovery rate correctionDifferent neuropsychiatric disordersCortical surface areaBrain cohortCortical thicknessIndependent cohortPsychiatric disordersUse disordersMatter volumeSubcortical structuresSubstance dependenceDiseaseSpatial Multiomics Analysis in Psychiatric Disorders.
Mao Q, Huang S, Luo X, Liu P, Wang X, Wang K, Zhang Y, Chen B, Luo X. Spatial Multiomics Analysis in Psychiatric Disorders. EC Psychology And Psychiatry 2023, 12: 1-5. PMID: 37424930, PMCID: PMC10328214.Peer-Reviewed Original ResearchPsychiatric disordersAlzheimer's diseaseCommon psychiatric disordersCertain brain regionsRisk genesMiddle temporal gyrusMultiomics analysisAutism spectrum disorderAD pathologyDisease progressionOlfactory bulbSpectrum disorderMouse modelPsychiatric diseasesHuman hippocampusBrain regionsNeuropsychiatric disordersTemporal gyrusLiterature searchAid diagnosisDisordersTranscriptional signatureDiseaseHippocampusSpatial transcriptomic analysis
2021
Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease
Taximaimaiti R, Luo X, Wang XP. Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease. Current Neuropharmacology 2021, 19: 2233-2249. PMID: 33998990, PMCID: PMC9185775, DOI: 10.2174/1570159x19666210517115706.Peer-Reviewed Original ResearchConceptsNon-pharmacological treatmentExcessive daytime sleepinessRestless legs syndromeRapid eye movementSleep disordersParkinson's diseaseSide effectsCommon non-motor symptomSleep behavior disorderNon-motor symptomsCommon sleep disorderDeep brain stimulationSleep hygiene educationRelative side effectsQuality of lifeCognitive behavior therapyLegs syndromePD patientsPharmacological treatmentComplementary therapiesDaytime sleepinessSleep qualityBrain stimulationBehavior disorderDisease
2020
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
Mao Q, Wang X, Chen B, Fan L, Wang S, Zhang Y, Lin X, Cao Y, Wu YC, Ji J, Xu J, Zheng J, Zhang H, Zheng C, Chen W, Cheng W, Luo X, Wang K, Zuo L, Kang L, Li CR, Luo X. KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease. Frontiers In Neuroscience 2020, 14: 651. PMID: 32655362, PMCID: PMC7324786, DOI: 10.3389/fnins.2020.00651.Peer-Reviewed Original ResearchPutamen gray matter volumesSubstantia nigra pars compactaGray matter volumeParkinson's diseaseMRNA expressionSingle nucleotide polymorphismsPD riskIndependent cohortMatter volumeDevelopment of PDPars compactaDopaminergic neuronsPutamenPutamen volumeSignificant associationPD associationsRisk allelesDiseaseSelective lossCohortGene variants
2019
Putamen gray matter volumes in neuropsychiatric and neurodegenerative disorders.
Luo X, Mao Q, Shi J, Wang X, Li CR. Putamen gray matter volumes in neuropsychiatric and neurodegenerative disorders. World Journal Of Psychiatry And Mental Health Research 2019, 3 PMID: 31328186, PMCID: PMC6641567.Peer-Reviewed Original ResearchGray matter volumePutamen volumeNeurodegenerative disordersMatter volumePutamen gray matter volumesSpectrum disorderParkinson's spectrum disordersAttention deficit hyperactivity disorderSchizophrenia spectrum disordersDeficit hyperactivity disorderMultiple sclerosisLewy bodiesObsessive-compulsive spectrum disordersMajor depressionTreatment outcomesMotor impairmentDopaminergic processesNeurodegenerative conditionsAmphetamine dependenceBipolar disorderAlzheimer's diseaseCognitive deficitsHuntington's diseaseDiseaseHyperactivity disorder
2017
Bayesian Cox Proportional Hazards Model in Survival Analysis of HACE1 Gene with Age at Onset of Alzheimer's Disease
Wang KS, Liu Y, Gong S, Xu C, Xie X, Wang L, Luo X. Bayesian Cox Proportional Hazards Model in Survival Analysis of HACE1 Gene with Age at Onset of Alzheimer's Disease. International Journal Of Clinical Biostatistics And Biometrics 2017, 3 PMID: 29430571, PMCID: PMC5806706, DOI: 10.23937/2469-5831/1510014.Peer-Reviewed Original ResearchCox proportional hazards modelCox regression modelProportional hazards modelRisk of ADAAO of ADHACE1 geneAlzheimer's diseaseSurvival analysisHazards modelHazard ratioSingle nucleotide polymorphismsBayesian Cox proportional hazards modelMultiple logistic regression modelRegression modelsConfidence intervalsChronic neurodegenerative diseasesLogistic regression modelsAD patientsOnset (AAO) of ADG haplotypeNeurodegenerative disordersNeurodegenerative diseasesDiseaseStrong associationCommon formAnalysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol
Chen Y, Xu C, Harirforoosh S, Luo X, Wang KS. Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol. Journal Of Psychiatric Research 2017, 96: 65-72. PMID: 28987514, PMCID: PMC6195678, DOI: 10.1016/j.jpsychires.2017.09.021.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAgedAged, 80 and overAlzheimer DiseaseCase-Control StudiesCerebellumCholesterolComputer SimulationFamilyGene ExpressionGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMiddle AgedNeoplasmsPolymorphism, Single NucleotideReceptor-Like Protein Tyrosine Phosphatases, Class 2ConceptsRisk of ADRisk of cancerAlzheimer's diseaseAAO of ADSingle nucleotide polymorphismsTotal cholesterol levelsMultiple logistic regressionLDL cholesterolTotal cholesterolCholesterol levelsAD patientsCancer riskMultiple linear regression analysisLinear regression analysisNeuropsychiatric disordersLogistic regressionDiseaseCancerWilcoxon testExpression levelsRiskRegression analysisGene expression levelsHuman brainGenetic variantsFamily-based association analysis of NAV2 gene with the risk and age at onset of Alzheimer's disease
Wang KS, Liu Y, Xu C, Liu X, Luo X. Family-based association analysis of NAV2 gene with the risk and age at onset of Alzheimer's disease. Journal Of Neuroimmunology 2017, 310: 60-65. PMID: 28778446, PMCID: PMC6167010, DOI: 10.1016/j.jneuroim.2017.06.010.Peer-Reviewed Original ResearchConceptsRisk of ADAlzheimer's diseaseSingle nucleotide polymorphismsAAO of ADHuman brain regionsNervous system developmentApoE expressionOnset (AAO) of ADBrain regionsDiseaseSignificant expressionRiskMarker analysisGenetic variantsAssociationFamily-based association analysisHaplotype analysisPresent studyEquation statisticsAgeFirst studyOnsetFamily-based associationFamily-based sampleExpressionTranscriptome-wide piRNA profiling in human brains of Alzheimer's disease
Qiu W, Guo X, Lin X, Yang Q, Zhang W, Zhang Y, Zuo L, Zhu Y, Li CR, Ma C, Luo X. Transcriptome-wide piRNA profiling in human brains of Alzheimer's disease. Neurobiology Of Aging 2017, 57: 170-177. PMID: 28654860, PMCID: PMC5542056, DOI: 10.1016/j.neurobiolaging.2017.05.020.Peer-Reviewed Original Research
2015
Significant association between rare IPO11‐HTR1A variants and attention deficit hyperactivity disorder in Caucasians
Zuo L, Saba L, Lin X, Tan Y, Wang K, Krystal JH, Tabakoff B, Luo X. Significant association between rare IPO11‐HTR1A variants and attention deficit hyperactivity disorder in Caucasians. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2015, 168: 544-556. PMID: 26079129, PMCID: PMC4851708, DOI: 10.1002/ajmg.b.32329.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAttention Deficit Disorder with HyperactivityBeta KaryopherinsBlack or African AmericanFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic VariationHumansMaleMiddle AgedPolymorphism, Single NucleotideQuantitative Trait LociReceptor, Serotonin, 5-HT1ARisk FactorsWhite PeopleConceptsAttention deficit hyperactivity disorderDeficit hyperactivity disorderNeuropsychiatric disordersRare variantsHyperactivity disorderDifferent neuropsychiatric disordersRNA expression changesIndependent cohortSignificant associationSignificant regulatory effectDisordersCaucasiansEuropean descentRegulatory effectsHuman brainDiseaseAssociationCis-eQTL analysisIPO11African descentExpression changesSubjectsCohortFalse discovery rateVariants
2013
Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?
Lu L, Wu Y, Zuo L, Luo X, Large PJ. Intestinal microbiome and digoxin inactivation: meal plan for digoxin users? World Journal Of Microbiology And Biotechnology 2013, 30: 791-799. PMID: 24105082, DOI: 10.1007/s11274-013-1507-x.Peer-Reviewed Original ResearchConceptsDigoxin inactivationIntestinal microbiomeDigoxin usersArginine supplementsInactivation of digoxinBioavailability of digoxinHeart diseaseEpidemiological dataAnimal modelsMeal planTherapeutic agentsMetabolism of argininePotential interventionsDigoxinDiseaseDigoxin activityHuman diseasesRecent studiesMicrobiomeSupplementsBioavailabilityInactivationAgents